Sign in4 stories
The company said 54% of evaluable patients hit DORIS remission at 12 months and plans to begin pivotal lupus nephritis trial start-up activities in the fourth quarter of 2026.
SEC filing
The company also disclosed FDA clearance of an IND for a new solid tumor cell therapy and outlined plans for an in vivo CAR-T pipeline.
SEC filing
The company also flagged a Q3 2026 regulatory filing for ADI-212 in prostate cancer and said cash should last into the second half of 2027.
SEC filing
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
SEC filing